Yazar "Ertay, Turkan" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim Yok
    Öğe
    Enzymatic synthesis of I-125/131 labeled 8-hydroxyquinoline glucuronide and in vitro/in vivo evaluation of biological influence
    (Pergamon-Elsevier Science Ltd, 2011) Yesilagac, Reyhan; Unak, Perihan; Medine, E. Ilker; Ichedef, Cigdem A.; Ertay, Turkan; Muftuler, F. Z. Biber
    8-Hydroxyquinoline (8-OHQ) is a long-known molecule which due to its metal-complexation ability is frequently used for analysis. It is also called oxine. Oxine and derivatives have been investigated to process antitumor and antimicrobial activities. 8-Hydroxyquinolyl-glucuronide (8-OHQ-Glu) was enzymatically synthesized using microsome preparates separated from Hutu-80 cells, labeled with I-125 to perform a radionuclide labeled prodrug and investigated of its biological affinities on Hutu-80 (human duodenum intestinal adenocarcinoma), Caco-2 (human colorectal adenocarcinoma), Detroit 562 (human pharynx adenocarcinoma) cells and ACBRI 519 (primary human small intestine epithelial cells) in this work. UDP-glucuronyl transferase (UDPGT) rich microsome preparates, which are used for glucuronidation in enzymatic synthesis, were extracted from Hutu-80 cells. 8-OHQ-Glu components were labeled using iodogen method with I-125 and I-131. Structural analyses were performed with LC/MS/MS, H-1 NMR and C-13-MMR for identify and measure chemical constituents. Results confirmed expected molecular structure. 8-OHQ-Glu could successfully radioiodinated with I-125/131 according to iodogen method. I-125-8-OHQ-glucuronide incorporated with human gastrointestinal cancer cells such as Detroit-562 (human pharynx adenocarcinoma) (12.6%), Caco-2 (human colorectal adenocarcinoma) (7.8%), Hutu-80 (human duodenum intestinal adenocarcinoma) (9.5%) and ACBRI 519 (primary human small intestine epithelial cells) (6.40%). I-131-8-OHQ-Glu was tested in mice bearing subcutaneously implanted Caco-2 colorectal adenocarcinoma cells. The results demonstrated that radioiodinated 8-OHQ-Glu may be promising anticancer prodrug. (C) 2010 Elsevier Ltd. All rights reserved.
  • Küçük Resim Yok
    Öğe
    A new agent for sentinel lymph node detection: preliminary results
    (Springer, 2011) Bekis, Recep; Medine, Ilker; Dagdeviren, Kagan; Ertay, Turkan; Unak, Perihan
    Sentinel lymph node detection is widely used to identify lymph nodes that receive lymphatic drainage from a primary tumor. (99m)Tc labeled iron oxide nanoparticles were prepared to invent a new colorful radioactive agent for sentinel lymph node detection. Iron oxide nanoparticles were produced by co-precipitation of FeCl(3) and FeCl(2) in the presence of NaOH. Then iron oxide nanoparticles were labeled with (99m)Tc. (99m)Tc labeled nanoparticles (7.4 MBq/0.1 mL) were intradermally injected in the distal hind limb of 16 rabbits. Dynamic and static lymphoscintigraphic images were taken for 24 h. Labeling efficiencies of (99m)Tc-iron oxide nanoparticles were over 99%. Their sizes are between 50 and 60 nm. (99m)Tc-iron oxide nanoparticles were accumulated in the popliteal lymph node in 11 of 16 rabbits (69%). Retention of nanoparticles in the popliteal lymph node was obvious at from 2nd through 24th hours. The radioactive lymph node was identified easily by gamma probe. The popliteal lymph node was excised and established for radioactivity and black dye. These black and radioactive nanoparticles may be potential agent successfully used for sentinel lymph node detection.
  • Küçük Resim Yok
    Öğe
    A New Tc-99m Labeled Peptide: Tc-99m beta-Casomorphin 6, Biodistribution and Imaging Studies on Rats
    (Kafkas Univ, Veteriner Fakultesi Dergisi, 2017) Ertay, Turkan; Unak, Perihan; Eren, Mine Sencan; Biber Muftuler, Fazilet Zumrut; Ozdogan, Ozhan; Ulker, Ozden; Yesilagac, Reyhan; Durak, Hatice
    Peptide radiopharmaceuticals have an increasing significance in nuclear medicine practice. beta-casomorphin is a digestive peptide with 6 amino acids (Tyr-Pro-Phe-Pro-Gly-Pro). N terminal amino acid chain mainly tyr-pro-phe-pro structured exogen opioid peptid type beta cosomorphin are beta-receptor agonistic activity with priority. Animal studies show that beta-casomorphins can act as opioid receptor agonists. The aim of this study was to label beta-casomorphin with (99m) Tc and to examine its usefulness as an opioid receptor binding radiopharmaceutical in Albino Wistar rats and cancer cells. beta-casomorphin was labeled with (99m) Tc radionuclide using bifunctional chelating agent. Quality control studies were done by Instant Thin layer chromatography (ITLC) and High performance liquid chromatography (HPLC) methods. Binding efficiency of the compound was more than 99%. It was observed as stable for at least 3 h at room temperature. Lipophilicity was also performed for labeled molecule. Imaging studies for (99m) Tc labeled molecule was done in rats by using gamma camera. For biodistribution studies; (99m) Tc labeled molecule was injected to the rats from tail vein and radioactivity per gr weight of each organ was measured as count per second (cps). Receptor specificity was evaluated in imaging and biodistribution studies in experimental animals. Cell labeling studies were also performed on breast and ovarien cancer cells. In terms of evaluating the biodistribution of (99m) Tc-beta-casomorphin molecule in rats, uterus and ovary displayed high involvement. It was also confirmed by cell labeling studies. If the radiopharmaceutical is radiolabeled with therapeutic radionuclides it would be useful for therapy for uterus, ovary and breast tumors.
  • Küçük Resim Yok
    Öğe
    Tc-99m-D-Penicillamine-Glucuronide: Synthesis, Radiolabeling, In Vitro and In Vivo Evaluation
    (Mary Ann Liebert Inc, 2011) Teksoz, Serap; Ichedef, Cigdem Acar; Ozyuncu, Seniha; Muftuler, Fazilet Zumrut Biber; Unak, Perihan; Medine, Ilker Emin; Ertay, Turkan; Eren, Mine Sencan
    The current study was aimed at synthesizing a glucuronide derivative of D-penicillamine (D-PA) to be used for imaging purposes. First of all, D-PA-glucuronide (D-PA-Glu) was synthesized by experimental treatments starting with uridine 5'-diphospho-glucuronosyltransferase enzyme rich microsome preparate. Then, the synthesized compound was labeled with technetium (Tc-99m) by using a reduction method with stannous chloride. Quality controls were performed by using high-performance liquid chromatography and thin-layer radio chromatography (TLRC). Radiolabeling yield of Tc-99m-D-PA-Glu was more than 98% according to TLRC results. In vitro evaluations of radiolabeled complexes were investigated on PC-3 human prostate cancer cells. Tc-99m-D-PA-Glu exhibited more accumulation on PC-3 cells versus Tc-99m-D-PA at 240 minutes. In order to determine its radiopharmaceutical potential, biodistribution studies were carried out in male Albino Wistar rats. The biodistribution results of Tc-99m-D-PA-Glu, showed the highest uptake in prostate at 120 minutes postinjection with the main excretion route being through kidneys and bladder. Tc-99m-D-PA-Glu and Tc-99m-D-PA have exhibited different biodistribution results.